Mirion Technologies, Inc. Class A (MIR)

Mirion Technologies' stock has experienced fluctuations over the past six months, with a 52-week high of $30.28 and a low of $13.11. As of early April 2026, the stock price was around $19.00, representing a 39.30% increase over the past year, but a 22.6% decline year-to-date as of March 22, 2026. Key events impacting the stock include Q4 2025 earnings, executive appointments in February 2026, participation in Citi's 2026 Global Industrial Tech and Mobility Conference, selection of Mirion Crew Active Dosimeters for NASA's Artemis II Mission, and optimism following President Trump's executive orders aimed at accelerating approvals for nuclear reactors in May 2025.

Demand for Mirion Technologies' products and services exhibits seasonality, with the first and third quarters typically lighter than the second and fourth quarters, aligning with the outage season in the nuclear power business. Historical stock price data suggests that February has the highest probability of positive returns for MIR stock, while March has the lowest.

Mirion Technologies, Inc. is a global leader in radiation detection, measurement, analysis, and monitoring solutions, operating within the Industrials sector, specifically in the Specialty Industrial Machinery industry. The company operates through two segments: the Medical Segment, which focuses on improving cancer care delivery through solutions for radiation therapy, nuclear medicine, and personal dosimetry, and the Nuclear & Safety Segment (Industrial Segment), which advances nuclear energy and addresses radiation safety across nuclear power, defense, laboratories, research, and other industrial sectors.

Headquartered in Atlanta, Georgia, USA, Mirion Technologies employs approximately 2,800 to 3,281 people and operates in 12 countries. The company conducts research and development, manufacturing, and calibration activities across North America, Europe, and Asia, delivering solutions to customers in more than 50 countries. In fiscal year 2024, sales to customers in the United States and Canada accounted for approximately 47% of total revenue, with an additional 35% and 15% from other regions.

Mirion Technologies has a strong brand reputation as a global leader in radiation safety, science, and medicine, with widespread adoption in cancer centers and nuclear power plants. The selection of Mirion Crew Active Dosimeters for NASA's Artemis II Mission is a significant positive event. The company faces challenges related to supply chain management, dependency on government contracts, geopolitical tensions, and regulatory changes.

Mirion Technologies' ownership is primarily held by institutional investors, reaching 86.05% by June 2025. As of April 9, 2026, 78.51% of the stock is held by institutions, and 6.30% by insiders. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and T. Rowe Price Investment Management, Inc. Thomas D. Logan has served as CEO since 2005 and became Chairman of the Board in February 2025. Mirion Technologies became a publicly traded entity on the NYSE in October 2021 following a SPAC merger with GS Acquisition Holdings Corp II.